Meeting
2013 ASCO Annual Meeting
Long-term survival in patients with metastatic melanoma who received ipilimumab in four phase II trials.
Authors
Celeste Lebbé
Hôpital Saint-Louis, Paris, France
Celeste Lebbé , Jeffrey S. Weber , Michele Maio , Bart Neyns , Kaan Harmankaya , Omid Hamid , Steven O'Day , Kevin M. Chin , Diane Opatt McDowell , Lori Cykowski , Brent McHenry , Jedd D. Wolchok
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Melanoma/Skin Cancers
Clinical Trial Registration Number
NCT00162123
Citation
J Clin Oncol 31, 2013 (suppl; abstr 9053)
DOI
10.1200/jco.2013.31.15_suppl.9053
Abstract #
9053
Poster Bd #
45H
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
A biomarker-guided Bayesian response-adaptive phase II trial for metastatic melanoma: The Personalized Immunotherapy Platform (PIP) trial design.
First Author: Serigne N. Lo
Poster
2015 ASCO Annual Meeting
One-year overall survival (OS) and biomarker correlates from a phase II study of ipilimumab (IPI) with carboplatin and paclitaxel (CP) in patients with unresectable stage III or IV metastatic melanoma (MM).
First Author: Rahima Jamal
Poster
2014 ASCO Annual Meeting
Final overall survival from a phase 3 trial of nab-paclitaxel versus dacarbazine (DTIC) in chemotherapy-naive patients with metastatic melanoma.
First Author: Evan Hersh
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Subgroup analyses of the phase 3 CAIRO3 trial: Association of number and total volume of metastases on survival in patients with metastatic colorectal cancer based on a deep-learning automatic segmentation model.
First Author: Koen Zwart